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Abstract
Objectives To compare the effect and cost effectiveness of bivalent
and quadrivalent human papillomavirus (HPV) vaccination, taking into
account differences in licensure indications, protection against
non-vaccine type disease, protection against disease related to HPV
types 6 and 11, and reported long term immunogenicity.
Design A model of HPV transmission and disease previously used to
inform UK vaccination policy, updated with recent evidence and
expanded to include scenarios where the two vaccines differ in duration
of protection, cross protection, and end points prevented.
Setting United Kingdom.
Population Males and females aged 12–75 years.
Main outcome measure Incremental cost effectiveness ratios for both
vaccines and additional cost per dose for the quadrivalent vaccine to be
equally cost effective as the bivalent vaccine.
Results The bivalent vaccine needs to be cheaper than the quadrivalent
vaccine to be equally cost effective, mainly because of its lack of
protection against anogenital warts. The price difference per dose ranges
from a median of £19 (interquartile range £12–£27) to £35 (£27–£44)
across scenarios about vaccine duration, cross protection, and end
points prevented (assuming one quality adjusted life year (QALY) is
valued at £30 000 and both vaccines can prevent all types of HPV related
cancers).
Conclusions The quadrivalent vaccine may have an advantage over
the bivalent vaccine in reducing healthcare costs and QALYs lost. The
bivalent vaccine may have an advantage in preventing death due to
cancer. However, considerable uncertainty remains about the differential
benefit of the two vaccines.
Introduction
Human papillomavirus (HPV) infection is a necessary cause of
cervical cancer1 and is associated with other anogenital cancers2
and anogenital warts. It may also be involved in some head and
neck cancers.3 Two vaccines that protect against HPV infection
and disease are now licensed for use in the United States and
the European Union. Cervarix is a bivalent vaccine targeting
HPV types 16 and 18, which are responsible for over 70% of
cervical cancer cases worldwide.4 Gardasil is a quadrivalent
vaccine that again targets HPV types 16 and 18, but also targets
HPV types 6 and 11, which cause most cases of anogenital
warts5 as well as recurrent respiratory papillomatoses.6 The
quadrivalent vaccine has also shown protection against precursor
lesions to vulval, vaginal, and anal cancers.7 8 More recently,
the bivalent vaccine has shown efficacy against anal infection,
suggesting potential protection against anal cancer.9 Both the
quadrivalent and bivalent vaccines show varying degrees of
protection against oncogenic HPV types not included in the
vaccines.10 11 12
Several countries procure one of the vaccines for publicly funded
vaccination programmes. For instance, Australia, Denmark, and
France procure the quadrivalent vaccine, whereas the UK and
the Netherlands use the bivalent vaccine. The choice between
vaccines is not straightforward as they differ in valency, licensed
indications, cross protective potential, and long term
immunogenicity,13 as well as possible tender price.14 In the UK
a publicly funded HPV vaccination programme was started in
2008, with routine vaccination offered to schoolgirls aged 12–13
years and a two year catch-up for girls up to the age of 18
years.15 A competitive adjudication process informed by
economic modelling16 resulted in a three year tender for the
programme being awarded to the manufacturers of the bivalent
vaccine.
The previous economic model suggested that the bivalent
vaccine would have to be about £15–£23 cheaper per dose to
be equally cost effective as the quadrivalent vaccine because of
the lack of protection against anogenital warts.16 Since then,
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further evidence has emerged to differentiate the two vaccines
in terms of vaccine efficacy in long term follow-up of vaccinated
cohorts as well as protection against genital warts, non-vaccine
HPV types, and non-cervical diseases related to HPV infection.
In addition, recent epidemiological and modelling studies have
enabled better estimates of the burden of cervical cancers,17
anogenital warts,18 19 recurrent respiratory papillomatoses,20 low
grade lesions due to HPV 6 and 11,21 and the apparent increase
in diseases caused by non-vaccine HPV types after vaccination
because of misattribution of disease to vaccine HPV types
(unmasking).22
Here we discuss key issues affecting the comparative cost
effectiveness of the two vaccines and use the most recent
evidence to estimate how much their price must differ for them
to be equally cost effective.
Methods
Methodological assumptions
Apreviously described transmission dynamicmodel of infection
and disease related to specific types of HPV (incorporating
adenocarcinomas, non-cervical cancers, and cancers not due to
HPV types 16 and 18)16 was adjusted in order that the
pre-vaccination burden of disease incorporated data from
recently published studies (see below). The incremental costs
and gains in quality adjusted life years (QALYs) of an HPV
vaccination programme using either the quadrivalent or bivalent
vaccine were estimated. Vaccination was assumed to start in
September 2008 with a school based programme for 12 year
old girls, and a catch-up campaign up to age 18 staggered over
two years.23 In order to simulate a decision implemented in
September 2011, the costs and benefits of the initial three years
of vaccination were not counted. Costs were inflated to 2008-9
prices using the Hospital and Community Health Services pay
and prices index.24 Costs and benefits were discounted at 3.5%
per year in the base case, with a time horizon of 100 years. All
costs were estimated from the perspective of the healthcare
provider. One QALYwas assumed to be valued at £20 000–£30
000, which is the threshold for cost effectiveness used by the
National Institute for Health and Clinical Excellence (NICE).25
Disease due to oncogenic HPV types
Cervical cancer
A multisite study of HPV prevalence in women with cervical
cancer indicated that the proportion of cervical cancers in
England due to vaccine HPV types may be higher than
previously estimated.17DNA of HPV type 16 or 18 was detected
in 76.4% (95% confidence interval 71.0% to 81.1%) of
specimens of residual squamous cell carcinoma and 81.9%
(73.2% to 88.2%) of residual adenocarcinoma specimens. Some
of these specimens also had DNA from other high risk HPV
types which may have caused the cancer; however, the
possibility of the cancer not being caused by HPV 16 or 18 is
subsequently adjusted for in our model (see subsection on
unmasking, below). Furthermore, 4.2% of squamous cell
carcinomas and 4.8% of adenocarcinomas had no detectable
high risk HPV. If it is assumed that this was due to lack of assay
sensitivity and that the missing types had the same distribution
as specimens with high risk HPV types detected, then the
proportion of cancers attributable to HPV 16 and 18 would rise
further. Hence the rate at which individuals develop invasive
cancer in our previous model was increased by an appropriate
amount in order to achieve a higher proportion of vaccine
preventable cancers, ensuring that the median proportion of
cancers attributable to HPV 16 or 18 was within the range
suggested in the study.
Non-cervical cancer
Currently there are data indicating that quadrivalent vaccination
protects against intraepithelial neoplasias of the vulva, vagina,
and anus that can progress to invasive carcinoma.7 8 In addition,
penile and oropharyngeal cancers have been linked with
infection with HPV 16 or 18.2 The bivalent vaccine had not been
evaluated for non-cervical end points in clinical trials at the time
this analysis was conducted, although there seemed no reason
to expect that it would not show protection against the same
end points related to HPV 16 and 18 as the quadrivalent vaccine.
Recently, the bivalent vaccine has been shown to protect against
anal infection.9
Two scenarios about the effect of vaccination on non-cervical
cancers were considered. In the optimistic scenario, it was
assumed that all cancers attributable to HPV 16 and 18 were
potentially preventable by vaccination. Protection against
cancers due to other HPV types for which the vaccines have
cross protective efficacy was assumed in some scenarios (see
table 1⇓). In the pessimistic scenario, it was assumed that the
quadrivalent vaccine protected against cervical, vulval, vaginal,
and anal cancers, and the bivalent vaccine protected against
cervical cancers only. The proportion of these cancers caused
by HPV 16, HPV 18, and non-vaccine HPV types was
determined using the most recent and comprehensive
meta-analyses available (see appendix 1 on bmj.com for details).
The acquisition of HPV and natural course of HPV related
cancers at non-cervical sites are poorly understood. Hence, it
is difficult to construct a model of HPV infection and disease
in these sites that accurately captures the underlying biological
processes. As a simplification, we assumed that the incidence
of HPV attributable non-cervical cancers (by age and year after
vaccination) will decrease at the same rate (proportionately) as
cervical cancer, as predicted by our transmission dynamicmodel.
Hence, slower developing cancers (which occur later in life)
will be reduced only many years after vaccination. This is
because they are more likely to be the result of HPV acquisition
many years before cancer onset. The incidence of these cancers
was obtained from cancer registration statistics for England in
2007.26
Disease due to HPV 6 and 11
Anogenital warts
Recently, the annual number of unique warts episodes leading
to patient attendances at either sexual health or general
practitioner clinics in England was estimated at about 156 000.19
Older studies based in specialist dermatology or gynaecology
clinics that tested HPVDNA in condylomas of anogenital warts
patients have found that HPV 6 or 11 is present in well over
90% of them.27 28 However, it is not certain whether HPV 6 or
11 caused the warts since other HPV types were often also
detected. A more recent study based in a Swedish sexual health
clinic found that HPV 6 and 11 were present only in 60% of
warts cases.29 Trials of the quadrivalent HPV vaccine, which
arguably provide the largest and best characterised cohorts,
found that the vaccine has an efficacy of 99% against
condylomas with vaccine HPV types present but only 82.8%
against all condylomas regardless of HPV type.5
We estimated the median number of wart episodes attributable
to HPV 6 and 11 each year to be 117 000 (range 105 000–135
000). This estimate was made using a previously described
model of warts associated with HPV 6 and 1130 that we refitted
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to include recent data on the age distribution of these wart
episodes.19 Using this refitted model, we selected the 330 best
fitting scenarios using the same definition of a good fitting
scenario as in our previous model (that is, a sum of squared
residual cut-off of 4). The resulting range of values that these
scenarios produce for the fraction of warts episodes attributable
to HPV 6 and 11 (67–86% of episodes) lies within the range of
uncertainty in the published literature (cited above).
Low grade screens
Based on a recent model,21 we estimated that infection with
HPV 6 or 11 increases the risk per cervical screen of an
abnormal (mild) smear by 0.054 (95% confidence interval 0.048
to 0.060) compared with not being infected with HPV.
Furthermore, data from the National Cervical Cancer Screening
Programme allowed us to estimate that each such smear has a
2.3% (2.1% to 2.5%) risk of resulting in a colposcopy. These
estimates were incorporated into the model as an incremental
benefit of quadrivalent vaccination.
Recurrent respiratory papillomatoses
Results of a survey of otorhinolaryngologists in the UK were
used to estimate that every year an additional 29.9 adult and
29.6 juvenile cases of recurrent respiratory papillomatoses
occur.20 Also, 2% of juvenile cases result in death. In the
optimistic scenario (where HPV vaccines prevent penile and
oropharyngeal cancer even though there is no direct evidence
from clinical trials for this), it was assumed that use of the
quadrivalent vaccine would reduce the incidence of new cases
at the same rate as the reduction in anogenital warts due to HPV
6 and 11.
Vaccine effects
Coverage
By April 2010, 84.1% of the first cohort of 12–13 year old
schoolgirls had received all three doses of HPV vaccine, 87.7%
had received at least two doses, and 89.8% had received at least
one dose.15However, uptake during the first year may have been
boosted by themedia attention attached to both HPV vaccination
and cervical screening in 2008. It was conservatively assumed
that an annual average of 80% of 12–13 year old schoolgirls
received the full course of vaccination. The cost of purchasing
the doses was inflated by 10% to account for doses given to
girls not receiving the full three doses (that is, a proportion of
the remaining 20% of girls). Coverage for the catch-up cohorts
was assumed to be 65% for 13–17 year olds, and 30% for the
cohort of 17–18 year olds leaving school, based on conservative
extrapolation of the same data.
Duration of protection
Both vaccines have shown lasting protection against infection
with HPV 16 and 18 and related disease in follow-up of up to
7.3 years for the bivalent vaccine31 or 9 years for the HPV 16
component of the quadrivalent vaccine.32 However, it is not
clear whether protection will persist beyond this period. Serum
antibodies for each type in the vaccine remain high 60 months
or more after vaccination.31 33 However, a small proportion of
individuals receiving the quadrivalent vaccine became
seronegative to HPV 6, 11, or 18 (though not to HPV 16, and
not with the bivalent vaccine34) by month 60.33 There were no
breakthrough cases of confirmed vaccine related disease, and
all vaccinated individuals showed a strong immune memory
response after administration of a challenge dose at month 61.
Hence it is unclear whether the decline in antibody titres has
any clinical significance.
We considered three alternative scenarios: (a) both vaccines
have 20 years’ average duration of protection, (b) both vaccines
have lifetime duration of protection, and (c) both vaccines have
lifetime duration of protection except for the quadrivalent
vaccine against types 6, 11, and 18, where protection lasted 20
years on average.
Cross protection
Protection against any lesion (cervical intraepithelial neoplasia
grade I or greater) caused by a non-vaccine oncogenic HPV
type tested for was reported as 23.4% for the quadrivalent
vaccine10 and 47.7% for the bivalent vaccine.12 Differences in
trial protocols and follow-up times mean it is difficult to
conclusively compare efficacy estimates for the two vaccines.
It is unclear whether cross protective efficacy will last, since
cross neutralising antibody titres are significantly lower than
type-specific titres.35
In the base case, we assumed that the bivalent and quadrivalent
vaccine had 47.7% and 23.4% efficacy respectively against
non-vaccine types, for the same duration as protection against
vaccine types.We also considered scenarios where the duration
of protection against non-vaccine types was shorter than for
vaccine types. Efficacy against cervical infection and disease
due to vaccine HPV types was assumed to be 100%, as in our
previous analyses.16 Vaccine protection against non-cervical
cancers caused by non-vaccine HPV types has yet to be shown
and was assumed to exist only in the optimistic scenarios (where
cross protective efficacy lasts as long as efficacy against vaccine
types).
The way non-vaccine oncogenic HPV types are modelled has
been previously described.30 Briefly, the model structure is the
same as for HPV types 16 and 18, except that all non-vaccine
oncogenic types are combined into a single composite type
because of lack of detailed information on individual types.
However, this method has been shown to overestimate the
infectivity of the composite type, and hence cause vaccine
impact to be underestimated.36 To avoid this, the prevalence of
the composite type was divided by 10 when we calibrated the
transmission probability (a measure of the infectivity of a
particular HPV type) to data; model predictions of prevalence
of specific HPV types are then subsequently multiplied back
up by 10. This effectively treats the composite type as 10
separate (but identical) subtypes, against which the vaccines
have 47.7% or 23.4% efficacy.
Unmasking
DNA typing studies of cervical neoplasia and cancer often find
more than one high risk HPV type present in a lesion.17 37
However, with laser capture microdissection, it is possible to
identify which HPV type is within the neoplastic lesion and
which are in the surrounding cells. This has revealed that each
neoplastic lesion contains only one high risk HPV type.38Hence,
it is likely that in multiply infected women some HPV types
give rise to different lesions and some HPV types are not
clinically relevant, rather than multiple types contributing to
the development of a single lesion. The laser capture
microdissection technique is expensive and labour intensive
and hence unlikely to be used for routine clinical typing or for
studies with large sample sizes in the foreseeable future. Hence
many studies apply algorithms such as an “oncogenic hierarchy,”
where, for example, a lesion with both HPV 16 and 18 DNA
detected is ascribed to HPV 16 because of this type’s higher
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oncogenic potential.39 Such an algorithm determines the most
likely causal HPV type in a lesion, but it is unlikely to be correct
all the time and will therefore underestimate the proportion of
lesions (and invasive cancers) due to high risk non-vaccine HPV
types that are ranked below HPV 16 and 18 in the hierarchy.
In order to correct for the underestimation of the proportion of
lesions due to non-vaccine HPV types, we used an individual
based cohort model fitted to data from an HPV typing study17
to determine the causal HPV types in each lesion and invasive
cancer (see appendix 1 on bmj.com for details). This found
increases of 10.3%, 5.6%, 6.0%, 5.1%, and 1.2% of cervical
intraepithelial neoplasia grades I, II, and III; carcinoma in situ;
and cervical cancers respectively due to non-vaccine HPV types
once the effect of unmasking was taken into account.22 The
number of cancers diagnosed was then adjusted for the fact that
a greater proportion of these are due to non-vaccine HPV types
(and hence less affected by vaccination). The number of positive
cytological screens and pre-cancerous lesions treated after
vaccination is also affected by unmasking; however, it is not
possible to estimate these differences without a full, individual
based model of infection transmission, vaccination, and
screening.
We did not consider the possibility of HPV type replacement
(a real increase in the prevalence of non-vaccine types due to
reduced competition) because there is no evidence in the
virological or epidemiological literature to suggest such a
phenomenon.40 Unmasking in non-cervical sites was not
considered as there are no equivalent UK based studies on
multiple infections in non-cervical pre-cancerous lesions and
cancers.
Scenarios
Data from the vaccine trials can be interpreted in several
different ways; in terms of the length of time the vaccines protect
against infection with HPV types and the degree to which they
prevent different end points. To accommodate these different
interpretations, we have defined 12 plausible scenarios (see
table 1⇓).
Costs and quality of life weights
Vaccination
The list prices of Gardasil and Cervarix are £88.50 and £80.50
a dose respectively.41 It is likely that an HPV vaccine will be
procured at a price below its list price for a UK-wide tender,
but the tender price is not known. To enable comparability
between equally priced bivalent and quadrivalent vaccines, we
fixed the price of vaccination at £84.50 per dose (this does not
affect estimates of the price difference for both vaccines to be
equally cost effective). Cost of administration was based on £28
paid by the Department of Health to primary care trusts for
delivering a full course of vaccination (Department of Health,
personal communication).
Screening
We retained the health related quality of life states related to
having a positive result from a cervical smear test or colposcopy
from our previous UK analysis.16 Costs were updated to reflect
the fact that England has now converted to liquid based
cytology. Costs for liquid based cytology were reported as
£28.11 (£25.40 in March 2006 prices).42 Each screen was
assumed to take 8.6 minutes of patient contact time with a
general practitioner,43 at a cost of £3 per minute.24 Hence the
total cost was estimated at £54. The cost of a colposcopy was
estimated to be £144 (£130 in March 2006 prices).42 44
Warts
The cost of treating anogenital warts was estimated in a study
based in eight sexual health clinics in England and Northern
Ireland to be £94 (95% confidence interval £84 to £104).18 This
excludes the cost of routine screening for other sexually
transmitted infections; the rationale for this exclusion is that the
benefits of such a screen (in terms of early diagnosis and
treatment of these infections) are also ignored. When costs of
treatment in general practices and tertiary care are included, the
total cost rises to £112 (£104 to £120).19 In the same study the
mean quality of life loss per episode of warts was estimated to
be 0.018 (0.0079 to 0.031) quality adjusted life years (QALYs).
The parameters estimated from this study are compared with
those from similar studies in appendix 1 on bmj.com.
Cervical cancer
TheQALYdetriment associated with cervical cancer in previous
studies has commonly been based on quality of life valuations
derived from expert panel consensus,45 valuations from healthy
individuals,46 or a survey using the Health and Limitations index
(HALex).47 No studies using the EuroQol EQ-5D quality of life
questionnaire in cervical cancer patients undergoing treatment
could be found. Valuations from healthy women based on the
“time-trade-off” method ranked stage I cervical cancer at 0.76
and stage II cervical cancer at 0.67.46 The second is close to the
quality of life value of 0.68 for “female genital cancer” estimated
from a survey of patients with chronic disease that made use of
the HALex instrument.47
After diagnosis, prognosis was estimated based on one and five
year cervical cancer survival figures from the Office for National
Statistics.48 After successful treatment, health related quality of
life improves. A Danish psychosocial study that followed
women regularly for 24 months after radiotherapy for cervical
cancer found that their satisfaction with their ability to carry
out daily activities, self rated quality of life, and self rated
overall physical condition steadily increased and was equal to
or close to that in controls after 18 months’ follow-up.49 50 A
Dutch study found a difference in EQ-5D scores of 0.061
between survivors of cervical cancer and controls. However,
the difference disappeared once demographic attributes were
controlled for.51
The uncertainty in these results is captured by a quality of life
decrement between 0.24 and 0.33 (based on a difference of 0.67
to 0.76 from perfect health) for patients upon cancer diagnosis.
They remain at this value for the duration of treatment, estimated
using the mean time from the start of the first hospital spell to
the end of the last hospital spell for a cervical cancer patient
reported in hospital episode statistics (HES). After their final
treatment, patients’ quality of life improves linearly until it
reaches a decrement of 0–0.061 after 18 months. It remains
there until the end of their lives.
Other HPV related cancers
Quality of life data on other HPV related cancers mostly do not
fulfil criteria for the reference case used by the National Institute
for Health and Clinical Excellence (NICE),25 so we had to rely
on alternative sources of data. We used data from the American
National Health Interview Survey (NHIS)47 for female genital
cancers (used for vulval and vaginal cancer) and gastrointestinal
cancers (used for anal cancer). For penile cancer, we used results
from the Institute of Medicine’s expert panel valuation using
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d5775 doi: 10.1136/bmj.d5775 Page 4 of 15
RESEARCH
the HUI-2 instrument,45 using results for locally invasive and
advanced stage cancers as two end points of a triangular
distribution. For oropharyngeal cancer, we used results from a
postal survey (with the EQ-5D questionnaire) of oral and
oropharyngeal cancer patients after primary surgery.52
Cancer patients recovering from treatment were assumed to
have the same quality of life as cervical cancer patients, although
their probability of survival each year after diagnosis was
assumed to be different.48 53 Anal cancer patients (ICD
(international classification of diseases) code C21) were assumed
to have the same survival prospects as other anorectal cancer
patients (ICD codes C19–C21), which may slightly
underestimate their survival.54
While there is a good study on the cost of treatment for cervical
cancer based on an audit of the Trent Cancer Registry,55 such
data do not exist for other HPV related cancers. Instead, we
examined three indicators of the relative cost of HPV related
cancers compared with cervical cancers: (a) the cost of hospital
spells in the HES database with operative procedures for HPV
related cancers, with the costing done by linking them to the
corresponding health related diagnosis (HRG) code using the
HRG4 2008–9 Reference Cost Grouper (www.ic.nhs.uk/
services/the-casemix-service/using-this-service/reference/
downloads/costing), (b) the ratio of the annual number of
hospital spells for each cancer type to the annual number of
cases of cancer registered by the Office for National Statistics
in 2007 (to estimate the average number of hospital spells per
cancer case), and (c) the direct medical costs of HPV related
cancers in the US, estimated in another study using secondary
data.56
The three methods give separate estimates of the relative costs
of treating different kinds of cancer. Cervical cancer costs from
the previous audit55 were used, with cancer staging based on a
Dutch study.57 In 2009 prices, this gave a cost of £15 000 per
cancer case. The relative cost of each non-cervical cancer
compared with cervical cancer, based on each of the three
methods, was then used to multiply the cost of cervical cancer.
Actual costs were then sampled from a triangular distribution
with end points at the smallest and largest of the three estimates,
and vertex at their geometric mean.
Recurrent respiratory papillomatoses
The QALY loss accrued to a patient with recurrent respiratory
papillomatosis was based on a lognormal distribution fitted to
a QALY loss of 1.3 (range 0.029–5.28), based on an estimated
loss of 0.31 (0.1–0.96) QALYs per year of the disease and
disease length of 4.2 (2.9–5.5) years in a US study.58 A recent
Canadian study estimated that the health utility of children with
recurrent respiratory papillomatoses is about 0.75 (based on a
visual analogue scale) to 0.76 (based on the HUI-3 instrument).59
The quality of life decrement from perfect health is quite close
to the estimated annual QALY loss in the US study. A Finnish
case-control study suggested that children with recurrent
respiratory papillomatoses may continue to have a lower quality
of life in adulthood compared with matched controls.60 This was
not incorporated here as the difference was small, and it was
not clear whether it might be due to residual confounding
(subjects were matched for age, sex, and smoking status only).
Treatment costs were estimated at £4900 per adult and £30 000
per child.20Any deaths due to juvenile onset recurrent respiratory
papillomatoses were assumed to occur at an average age of 4
years.61
Sensitivity analysis
Uncertainty in results was captured by drawing 10 000 samples
from combinations of (a) 2700 previously described scenarios
for oncogenic HPV types30 and 900 scenarios for HPV types 6
and 11 representing combinations of assumptions about the
natural course and epidemiology of HPV infection, and (b)
probability distributions representing uncertainty in economic
parameters (with sampling distributions shown in table 2⇓).
Sampling from both sets was conducted using the Latin
hypercube method. For economic parameters, normal,
lognormal, or beta distributions were assumedwhen quantitative
data about the uncertainty around parameters were available. If
they were not, triangular distributions based around several
point estimates were assumed.When only a single point estimate
was available, a normal distribution with coefficient of variation
0.25 was assumed.
Price difference
The price difference between equally cost effective bivalent and
quadrivalent vaccines was estimated by calculating the
difference between the net present values of the two vaccines
(monetary value in 2008–9 of all the cost savings and QALYs
gained over the 100 years of the model), divided by the number
of doses needed to achieve these benefits.
Results
Effect on disease
Use of either vaccine is expected to substantially decrease the
incidence of HPV related cancers regardless of which scenario
is assumed (see fig 1⇓). The benefit is greater when duration of
protection is assumed to be lifelong. By 2109, use of the
quadrivalent vaccine may be preventing a median of 700
(interquartile range 630–800) to 1000 (940–1100) cervical
cancer cases a year (depending on scenario), and the bivalent
vaccine about 730 (650–830) to 1100 (990–1200) cases. The
interquartile range is the difference acrossMonte Carlo samples
within the same scenario. The difference between the
quadrivalent and bivalent vaccine is not great, despite potentially
greater cross protection from the bivalent vaccine. This is true
even in scenarios where the quadrivalent vaccine has a shorter
duration of protection against HPV 18 (scenarios 3 and 6), since
most cervical cancers are related to HPV 16.
In addition, by 2109 vaccination may prevent about 620
(560–720) to 950 (900–1000) non-cervical cancer cases
annually. Even if vaccination protects only against end points
indicated in the vaccines’ licensure, quadrivalent vaccination
may prevent 430 (380–490) to 630 (950–670) vulval, vaginal,
and anal cancers a year by 2109. Use of the quadrivalent vaccine
is expected to decrease the incidence of vaccine type warts and
recurrent respiratory papillomatoses by up to 95% if duration
of protection is lifelong. However, the bivalent vaccine is likely
to be more effective in preventing death due to cancer. It may
prevent 1.1% (1.0–1.3%) to 4.1% (3.4–4.8%) more deaths due
to cancer if both vaccines protect against all HPV related cancer
end points.
Economic benefit
Themost important benefit of either vaccine in terms of reducing
healthcare costs and lost QALYs due to disease is in protecting
against cervical cancer and its precursor lesions (see fig 2⇓).
Protection against anogenital warts is also an important
additional benefit of the quadrivalent vaccine, because of their
high incidence and the proximity of their occurrence to the time
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of vaccination. Possible protection against non-cervical cancers,
while a substantial benefit, is less important in economic (cost
and quality of life) terms compared with cervical cancer
protection.
Cost effectiveness
The quadrivalent vaccine seems to be cost effective at a
threshold of £30 000 per QALY gained across all 12 of the
scenarios considered (see fig 3⇓). The incremental cost
effectiveness ratio of quadrivalent vaccination (compared with
no vaccination) ranges from £12 000 (£11 000–£14 000) to £19
000 (£17 000–£22 000) when protection against anal, penile,
and oropharyngeal cancers is assumed, and up to £22 000 (£19
000–£25 000) when only protection against licensed end points
is assumed. The incremental cost effectiveness ratio of bivalent
vaccination (compared with no vaccination) ranges from £16
000 (£14 000–£18 000) to £25 000 (£21 000–£28 000) with
protection against all cancer end points, and up to £41 000 (£34
000–£45 000) with protection against licensed end points only.
Hence when making pessimistic assumptions about duration of
protection and range of end points prevented, bivalent
vaccination may not be cost effective at £84.50 per dose.
Additional cost per dose of the quadrivalent
vaccine
If QALYs are valued at £30 000 each, then the additional cost
per dose (for a three dose course) of the quadrivalent vaccine
for it to be equally cost effective as the bivalent vaccine ranges
from £19 (£12–£27) to £38 (£30–£47) if both vaccines protect
against all HPV related cancer end points (see fig 4⇓). If the
vaccines are assumed to protect only against cancer end points
in their licensure, then the differential between threshold costs
per dose for the two vaccines is greater (median £48 to £68
across scenarios), due to protection against vulvar, vaginal, and
anal cancers being a benefit of quadrivalent vaccination only.
If QALYs are valued at only £20 000 each, the differential is
smaller (median £14 to £28, or £35 to £48 if only licensed end
points are protected against).
The quadrivalent vaccine’s protection against anogenital warts
seems more important than possible advantages of the bivalent
vaccine in terms of cervical cancer prevention, when measured
in terms of QALYs gained and costs prevented (fig 5⇓).
However, the bivalent vaccine may have an advantage in
preventing death due to cancer.
Effect of lower discounting of benefits
If the rate at which benefits are discounted is reduced to 1.5%
per annum, then the additional cost of an equally cost effective
quadrivalent vaccine increases to between £36 (£21–£53) and
£157 (£134–£178) per dose, depending on the strategy, when
a QALY is valued at £30 000. The uncertainty around the
estimates also increases, since this gives greater weight to
outcomes further in the future for which model predictions are
less certain. Note that a lower discount rate increases the present
value of the benefits of both cancer and warts prevention, but
the benefits of cancer prevention increase proportionately by
more, since they occur later in the future. However, the size of
the contribution to the vaccine cost difference from warts
prevention by the quadrivalent vaccine is much greater than that
of additional protection against cancer by the bivalent vaccine
in all the scenarios. Hence, overall reduction of the discount
rate favours the quadrivalent vaccine.
Discussion
Principal findings
In our previous analysis in 2008 to inform vaccine procurement
for the UK HPV immunisation programme, the median
additional price per dose for an equally cost effective
quadrivalent vaccine was estimated to be about £15 per dose
(for a vaccine with lifetime duration) to £23 per dose (for a
vaccine with 20 years duration).16 The estimates in most of the
scenarios presented here are greater than this for several reasons.
Firstly, the quadrivalent vaccine has now shown protection
against precursors to vulvar, vaginal, and anal cancer in clinical
trials, but the bivalent vaccine had not at the time the analysis
was conducted (more recently it has been shown to protect
against anal infection). If we assume that the two vaccines
protect against the same HPV 16 and 18 related end points
(which seems reasonable), the price differential narrows but is
still greater than in our 2008 analysis. This is because the
estimate of the quality of life detriment due to an episode of
warts has increased, based on the results of a new study on the
burden of anogenital warts.18 In particular, the study explicitly
asked respondents how long they had warts before seeking care;
in some cases respondents reported waiting for years before
they did.
Protection against HPV 6 and 11 related low grade lesions and
recurrent respiratory papillomatoses, while incremental benefits
of quadrivalent vaccination, does not have a large effect on the
cost differential.
Only when the scenario most favourable to bivalent vaccination
is assumed (both vaccines protect against the same HPV 16 and
18 end points, but the bivalent vaccine has a longer duration of
protection against HPV 18 and long lasting protection against
non-vaccine types) does the additional price per dose of an
equally cost effective quadrivalent vaccine drop below the
estimate in our previous analysis.
However, if the object of HPV vaccination is solely cancer
prevention, then the bivalent vaccine is likely to prevent more
cancers and cancer deaths than the quadrivalent vaccine.
Comparison with other studies
The choice between the two currently licensed HPV vaccines
has been subject to intense debate in countries such as Australia
and the UK with central vaccine procurement.62-66 Yet few
published studies have tried to estimate the price difference for
the two vaccines to be equally cost effective.
An Irish study67 found that the bivalent vaccine would have to
be 22% (or about €20 a dose) cheaper to be equally cost effective
as the quadrivalent vaccine because of lack of protection against
anogenital warts, assuming lifelong vaccine duration. A
Canadian study68 suggested that the difference should be about
C$35 a dose. Both were static models and hence did not take
into account indirect protection, nor did they assess potential
differences between the vaccines in terms of licensure end points
(besides warts), cross protection, or duration of protection. In
addition, other papers have estimated the effect on cost
effectiveness of particular features of one or both vaccines, such
as warts protection,69 impact on non-cervical cancers,70 cross
protection, and duration of protection.71
Our analysis is the first to integrate all these potential benefits
that may differentiate one vaccine over another into a single
analysis and to present price differentials per dose for a range
of scenarios in a way that can be immediately used for deciding
which vaccine to use in central procurement.
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Limitations
There are several limitations to this analysis. Firstly, HPV
vaccinemanufacturers have sought to differentiate their vaccines
from each other based on their composition (valency and
adjuvants), end points prevented, long term immunogenicity,
and protection against HPV types not included in the vaccine.
However, in some cases it is not clear to what extent these
differences affect clinical efficiency at the population level. For
instance, immunogenicity may not be a reliable marker of
clinical protection, cross protective efficacy may not prove to
be long lasting, and the lack of evidence for the protective effect
of bivalent vaccination on non-cervical end points may simply
reflect the failure of its manufacturers to investigate such effects.
Furthermore, reported cross protective efficacy against neoplasia
may not be accurate as it involves having to determine the causal
HPV type when there is more than one type present.
Consequently, we have developed a range of scenarios
representing different interpretations of trial data. These
scenarios are not equally likely: for example, it seems more
plausible that both vaccines can prevent all HPV related cancer
end points (scenarios 7–12) than simply the end points in their
indication (scenarios 1–6). As long term efficacy and population
level efficiency data become available, some of these scenarios
may seem unrealistic. However, given our present knowledge,
our models suggest that the range in estimated price differences
across the scenarios is large.
Secondly, only poor data are available on the natural course of
HPV related cancers in sites other than the cervix, even though
these account for a substantial portion of the burden of HPV
infection that is potentially preventable by vaccination. Hence
we did not realistically model the natural course of these cancers,
but instead imputed the age dependent reduction seen in cervical
cancers caused by vaccine HPV type infection. We had to
assume that the proportion of each cancer type attributable to
HPV is not age dependent, although there is evidence that this
may not be true for some cancers.2 In some cases (such as
oropharyngeal cancers) there is no consensus among
epidemiologists about the proportion of cancers caused by HPV.
The incidence of oropharyngeal cancers attributable to HPV
seems to be increasing in many countries for reasons that are
not fully understood, but we decided not to incorporate this
apparent increase as it is not yet clear whether this trend will
continue. Also, our method may overestimate the potential
reduction in male cancers, since a substantial proportion of them
occur in men who have sex with men (particularly for anal
cancer), who are currently not routinely vaccinated and who
may benefit less from herd immunity than heterosexual men.
Thirdly, because of data and model limitations, we have
represented non-vaccine HPV types as a single composite type.
To avoid overestimating the transmission probability of the
composite type,36 we have effectively treated this HPV type as
10 separate (but identical) subtypes. However, this correction
is an approximation, since the transmission probability and
vaccine efficacy against each of these subtypes is different.
Lastly, we have assumed that quadrivalent vaccination reduces
the incidence of recurrent respiratory papillomatoses at the same
rate as that of warts related to HPV 6 and 11. This assumption
is valid only if the delay between maternal HPV 6 and 11
infection and development of juvenile onset recurrent respiratory
papillomatosis is similar to the delay between HPV 6 and 11
infection and warts diagnosis. There is little information in the
literature to inform such an assumption, but we may have
slightly overestimated the speed of reduction of recurrent
respiratory papillomatoses given that they can occur in young
children some years after birth.
Conclusions and implications
In conclusion, our analysis shows that considerable uncertainty
remains about the differential benefit of the two available HPV
vaccines in terms of their efficacy against non-vaccine HPV
types; prevention of non-cervical cancer, warts, and recurrent
respiratory papillomatoses; and duration of protection. Clinical
and public health decisions about choice of HPV vaccine need
to take account of the whole spectrum of differences between
vaccines and the uncertainty around them. Based on recent
evidence, the price differential between the quadrivalent and
bivalent vaccine for both to be equally cost effective seems to
be larger than in our previous analysis,16 unless assumptions
most favourable to bivalent vaccination are assumed.
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Tables
Table 1| Plausible scenarios about the duration of vaccine protection and end points that the vaccines may protect against, as used in the
economic modelling comparing bivalent and quadrivalent human papillomavirus (HPV) vaccines
QuadrivalentBivalent
Scenario
HPV 6 or 11
end points
prevented
Cancer end
points
prevented
Duration of protectionCancer end
points
prevented
Duration of protection
Non-vaccine HPV
typesVaccine HPV types*
Non-vaccine HPV
typesVaccineHPV types*
Warts, mild
smears
Cervical,
vaginal, vulvar,
anal (all HPV
types)
20 years20 yearsCervical (all
HPV types)
20 years20 years1
LifetimeLifetimeLifetimeLifetime2
LifetimeLifetime (HPV 16), 20
years (others)
LifetimeLifetime3
Cervical (all
HPV types),
vaginal, vulvar,
anal (vaccine
HPV types
only)
10 years20 years10 years20 years4
20 yearsLifetime20 yearsLifetime5
20 yearsLifetime (HPV 16), 20
years (others)
20 yearsLifetime6
Warts, mild
smears,
recurrent
respiratory
papillomatoses
All (all HPV
types)
20 years20 yearsAll (all HPV
types)
20 years20 years7
LifetimeLifetimeLifetimeLifetime8
LifetimeLifetime (HPV 16), 20
years (others)
LifetimeLifetime9
Cervical (all
HPV types), all
others (vaccine
HPV types
only)
10 years20 yearsCervical (all
HPV types),
all others
(vaccine
HPV types
only)
10 years20 years10
20 yearsLifetime20 yearsLifetime11
20 yearsLifetime (HPV 16), 20
years (others)
20 yearsLifetime12
*Vaccine HPV types are 16 and 18 for bivalent vaccine, and types 16, 18, 6, and 11 for quadrivalent vaccine.
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Table 2| Parameters used in the economic modelling comparing bivalent and quadrivalent human papillomavirus (HPV) vaccines, and their
sampling distribution for the probabilistic sensitivity analysis
SourceDistributionMeanParameter
Other parameters
Costs
Wolstenholme et al55; De Rijke et al57Lognormal mean 15 000 (SD 9300)£15 000Treatment for cervical cancer
Relative cost of treatment (v cervical cancer):
Hu et al56; hospital and cancer registry dataTriangular (min 0.65, max 1.3, mode 0.75)0.91Vulvar and vaginal cancer
Triangular (min 0.48, max 1.5, mode 0.64)0.87Anal cancer
Triangular (min 0.87, max 1.1, mode 1.0)1.0Oropharyngeal cancer
Triangular (min 0.65, max 1.0, mode 0.67)0.77Penile cancer
Desai et al19Normal mean 112 (SD 4)£112Treatment for anogenital warts
Treatment for recurrent respiratory papillomatoses:
Hughes et al20 and unpublished dataLognormal mean 30 000 (SD 63 000)£30 000Juvenile cases
Lognormal mean 4900 (SD 5400)£4900Adult cases
Curtis24; Martin-Hirsch et al42; Karnon et al43Normal mean 54 (SD 13.5)£54Cytology test (liquid based)
Martin-Hirsch et al42; Brown et al44Normal mean 144 (SD 36)£144Colposcopy
Martin-Hirsch et al42; Brown et al44Normal mean 349 (SD 87)£349Pre-cancerous lesion treatment
British National Formulary41Fixed£84.50Vaccine price (per dose)
Department of Health, personal
communication
Fixed£9.33Vaccine administration (per dose)
Quality of life detriment
Treatment for
Myers et al46; Gold et al47Triangular (min 0.24, max 0.33, mode 0.285)0.285Cervical cancer
Gold et al47Triangular (min 0.16, max 0.52, mode 0.28)0.32Vulvar-vaginal cancer
Gold et al47Triangular (min 0.21, max 0.83, mode 0.49)0.51Anal cancer
Rogers et al52Normal mean 0.25 (SD 0.02)0.25Oropharyngeal cancer
Institute of Medicine45Triangular (min 0.2, max 0.38, mode 0.29)0.29Penile cancer
Klee et al49 50; Korfage et al51Triangular (min 0, max 0.061, mode 0.0305)0.0305Recovery from cancer
Jit et al16Normal mean 0.025 (SD 0.00625)0.025Positive cytology result
Positive cervical intraepithelial neoplasia result:
Jit et al16Normal mean 0.012 (SD 0.003)0.012Grade I
Normal mean 0.007 (SD 0.00175)0.007Grade II
Normal mean 0.054 (SD 0.00135)0.054Grade III
Woodhall et al18Normal mean 0.018 (SD 0.0059)0.018Episode of anogenital warts
Bishai et al58Lognormal mean 1.30 (SD 1.56)1.30Episode of recurrent respiratory papillomatosis
Hospital Episode StatisticsLognormal mean 0.116 (SD 0.36)0.116Time spent receiving treatment for cancer (years)
True proportion of cancers due to HPV 16 and 18
Howell-Jones et al17Normal mean 0.80 (SD 0.027)80%Squamous cell carcinomas
Normal mean 0.86 (SD 0.040)86%Adenocarcinomas
Chapman et al21Normal mean 0.54 (SD 0.030)5.4%Additional risk of mild smear if HPV 6 or 11 positive
Chapman et al21Normal mean 0.023 (SD 0.0072)2.3%Risk of colposcopy after mild smear if HPV 6 or 11 positive
Proportion of cancers due to HPV:
Literature review (see appendix 1 on
bmj.com)
Beta (p 690, q 780)47%Vulvar-vaginal cancer
Beta (p 55, q 77)42%Anal cancer
Beta (p 800, q 150)84%Oropharyngeal
Beta (p 340, q 620)36%Penile
Proportion of HPV attributed cancers due to HPV 16 or 18
Literature review (see appendix 1 on
bmj.com)
Beta (p 77, q 27)74%Vulvar-vaginal cacer
Beta (p 95, q 11)90%Anal cancer
Beta (p 760, q 56)93%Oropharyngeal cancer
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Table 2 (continued)
SourceDistributionMeanParameter
Other parameters
Beta (p 300, q 37)89%Penile cancer
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Figures
Fig 1 Estimated annual number of cases of cervical cancer, other HPV related cancers and vaccine HPV type warts in the
year 2109 under the scenarios 1–12 described in table 1 (median of 10 000 samples), given use of no vaccine, the
quadrivalent vaccine, or the bivalent vaccine. Error bars show interquartile range of 10 000 samples for each scenario (see
appendix 2 on bmj.com for numerical results)
Fig 2Discounted healthcare costs and QALYs saved over 97 years (2012–2109) of a quadrivalent or bivalent HPV vaccination
programme (2012 onwards) under the different scenarios described in table 1 (median of 10 000 samples) (see appendix
2 on bmj.com for numerical results and uncertainty intervals)
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Fig 3 Incremental cost effectiveness ratios for equally priced quadrivalent and bivalent vaccines under the different scenarios
described in table 1. Values show median (interquartile range) of 10 000 Latin hypercube samples
Fig 4 Additional cost per dose (for a three dose course) for the quadrivalent vaccine that makes it equally cost effective as
the bivalent vaccine under the different scenarios described in table 1 and with one QALY valued at either £20 000 or £30
000. Values show median (interquartile range) of 10 000 Latin hypercube samples
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Fig 5 Benefits of the quadrivalent and bivalent vaccine that contribute towards the difference in price for the two vaccines
to be equally cost effective (median of 10 000 samples). One QALY is assumed to be valued at £30 000. The two benefits
of the bivalent vaccine (additional cross protection and in some scenarios longer duration) contribute negatively towards
the price difference (that is, they make an equally cost effective quadrivalent vaccine cost less) (see appendix 2 on bmj.com
for numerical results and uncertainty intervals)
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